Valuation: Valneva SE Pref.

Market Cap 51Cr 58Cr 49Cr 44Cr 83Cr 5.6TCr 84Cr 582.6Cr 224.2Cr 2.86TCr 219.15Cr 214.37Cr 9.17TCr P/E 2026 *
-6.22x
P/E 2027 * 9.81x
Enterprise Value 65Cr 74Cr 61Cr 55Cr 104.41Cr 7.05TCr 105.76Cr 734.18Cr 282.53Cr 3.61TCr 276.17Cr 270.15Cr 12TCr EV / Sales 2026 *
4.29x
EV / Sales 2027 * 2.03x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 58Cr
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.38%+1.01%+27.49%+80.56% 6.01TCr
-2.45%-1.61%+4.90%+33.37% 4.82TCr
-1.73%-3.75%+29.89%+36.53% 4.43TCr
+1.88%+4.68%+356.21%+699.47% 4.4TCr
-0.59%+1.03%+8.51%+103.74% 4.16TCr
+3.32%+3.49%+11.18%+51.23% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-2.68%-8.57%-24.55%+338.04% 2.49TCr
Average +0.61%+1.97%+55.53%+162.21% 4.41TCr
Weighted average by Cap. +0.80%+1.83%+59.76%+153.22%

Financials

2026 *2027 *
Net sales 15Cr 17Cr 14Cr 13Cr 24Cr 1.64TCr 25Cr 171.18Cr 66Cr 840.54Cr 64Cr 63Cr 2.69TCr 28Cr 32Cr 27Cr 24Cr 46Cr 3.09TCr 46Cr 321.22Cr 123.61Cr 1.58TCr 120.83Cr 118.19Cr 5.06TCr
Net income -8.11Cr -9.21Cr -7.69Cr -6.94Cr -13Cr -883.2Cr -13Cr -92Cr -35Cr -451.51Cr -35Cr -34Cr -1.45TCr 5.31Cr 6.03Cr 5.03Cr 4.54Cr 8.56Cr 577.87Cr 8.67Cr 60Cr 23Cr 295.42Cr 23Cr 22Cr 947.12Cr
Net Debt 13Cr 15Cr 13Cr 11Cr 22Cr 1.46TCr 22Cr 151.58Cr 58Cr 744.31Cr 57Cr 56Cr 2.39TCr 6.25Cr 7.09Cr 5.92Cr 5.34Cr 10Cr 680.27Cr 10Cr 71Cr 27Cr 347.77Cr 27Cr 26Cr 1.11TCr
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.710EUR
Average target price
6.193EUR
Spread / Average Target
+128.52%

Quarterly revenue - Rate of surprise